Establishment Labs announced it has launched Motiva Implants in China. The commercial launch coincided with the Motiva China International Academic Conference that was held in Hainan, China; events also took place in Shanghai, Guangzhou, and Shenzhen. Establishment Labs received National Medical Products Administration, or NMPA, approval in China for Motiva(R) Implants in November 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ESTA:
- Establishment Labs to sell 2M shares at $25.00 in private placement
- Establishment Labs sees FY23 revenue $165M-$165.4M, consensus $164.92M
- Establishment Labs sees Q4 revenue $31.4M-$31.8M, consensus $31.47M
- Establishment Labs reports first U.S. commercial use for Motiva Flora SmoothSilk
- 3 Best Stocks to Buy Now, 12/25/2023, According to Top Analysts
